You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

TRYPAN BLUE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for trypan blue and what is the scope of patent protection?

Trypan blue is the generic ingredient in two branded drugs marketed by Dorc and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There are two drug master file entries for trypan blue. One supplier is listed for this compound.

Summary for TRYPAN BLUE
US Patents:0
Tradenames:2
Applicants:1
NDAs:2
Drug Master File Entries: 2
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 63
Clinical Trials: 5
Patent Applications: 63
What excipients (inactive ingredients) are in TRYPAN BLUE?TRYPAN BLUE excipients list
DailyMed Link:TRYPAN BLUE at DailyMed
Recent Clinical Trials for TRYPAN BLUE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
The Cleveland ClinicPhase 3
Lisa Dean Moseley FoundationPhase 3
Sheng HuEarly Phase 1

See all TRYPAN BLUE clinical trials

Pharmacology for TRYPAN BLUE
Drug ClassDiagnostic Dye
Mechanism of ActionDyes
Medical Subject Heading (MeSH) Categories for TRYPAN BLUE
Anatomical Therapeutic Chemical (ATC) Classes for TRYPAN BLUE

US Patents and Regulatory Information for TRYPAN BLUE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Dorc MEMBRANEBLUE trypan blue SOLUTION;OPHTHALMIC 022278-001 Feb 20, 2009 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Dorc VISIONBLUE trypan blue SOLUTION;OPHTHALMIC 021670-001 Dec 16, 2004 RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TRYPAN BLUE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Dorc MEMBRANEBLUE trypan blue SOLUTION;OPHTHALMIC 022278-001 Feb 20, 2009 ⤷  Subscribe ⤷  Subscribe
Dorc VISIONBLUE trypan blue SOLUTION;OPHTHALMIC 021670-001 Dec 16, 2004 ⤷  Subscribe ⤷  Subscribe
Dorc VISIONBLUE trypan blue SOLUTION;OPHTHALMIC 021670-001 Dec 16, 2004 ⤷  Subscribe ⤷  Subscribe
Dorc MEMBRANEBLUE trypan blue SOLUTION;OPHTHALMIC 022278-001 Feb 20, 2009 ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

TRYPAN BLUE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of Trypan Blue

Introduction

Trypan blue, a dye historically used for staining dead cells to determine cell viability, has been a staple in biological research for over a century. However, its use has been increasingly scrutinized due to several critical issues, including toxicity, accuracy concerns, and regulatory challenges. This article delves into the market dynamics and financial trajectory of trypan blue, highlighting the factors influencing its use and the emerging alternatives.

Historical Use and Market Presence

Trypan blue has been widely used in cell counting and viability assessments since its introduction. It was the gold standard for distinguishing between live and dead cells due to its exclusion from viable cells and uptake by dead cells[2][4].

Accuracy and Reliability Concerns

One of the primary challenges facing trypan blue is its accuracy and reliability. The dye is toxic to cells, leading to changes in cell viability over time. Even viable cells can be stained and killed by trypan blue within 5 to 30 minutes of exposure, which significantly underestimates cell viability[1][2].

Morphological Changes

Trypan blue can alter the morphology of dead cells, causing them to rupture and form diffuse objects, which can lead to over-estimation of cell viability. This phenomenon is not observed with other dyes like propidium iodide, highlighting the specific issues with trypan blue[2].

Subjective Interpretation

The use of trypan blue under bright-field microscopy introduces subjective variability among users. The staining patterns can be ambiguous, and different lab members may have different interpretations of what constitutes a dead or live cell[1].

Regulatory and Safety Issues

The European Chemical Agency (ECHA) has classified trypan blue as a Group 2B carcinogen, indicating it may cause cancer, genetic defects, and damage fertility or harm an unborn child. This classification has led to strict regulations and the requirement for special permits to use trypan blue in some European countries[1].

Compliance and Permit Requirements

In countries like Denmark, laboratories must obtain a permit to use trypan blue, and this permit is only granted if the use is strictly necessary. Laboratories must also implement standard operating procedures to minimize exposure and ensure safe disposal of trypan blue[1].

Market Impact of Regulatory Changes

The regulatory changes and safety concerns have significantly impacted the market for trypan blue. Laboratories are increasingly looking for safer and more accurate alternatives, which has led to a decline in the demand for trypan blue.

Economic Consequences

The need for permits, special handling procedures, and the potential health risks associated with trypan blue have increased the operational costs for laboratories. This has made trypan blue a less attractive option financially, especially when compared to safer and more accurate methods[1].

Emerging Alternatives

Several alternatives to trypan blue have emerged, offering improved accuracy and safety.

Fluorometric Assays

Fluorometric assays using dyes like acridine orange (AO) and 4′,6-diamidino-2-phenylindole (DAPI) provide superior accuracy in cell viability measurements. These dyes produce uniform staining patterns and are less subjective than trypan blue[1].

Propidium Iodide

Propidium iodide is another viable alternative that stains dead cells without the morphological changes and toxicity associated with trypan blue. It is widely used in cell viability assays and is considered a safer option[2][4].

Financial Trajectory

The financial trajectory of trypan blue is declining due to the increasing awareness of its limitations and the availability of better alternatives.

Decreasing Demand

As more laboratories adopt safer and more accurate methods, the demand for trypan blue is decreasing. This reduction in demand is expected to continue as regulatory pressures and safety concerns mount[1].

Investment in Alternatives

Companies are investing more in the development and marketing of alternative cell viability dyes. This investment is driven by the growing need for accurate and safe methods in cell counting and viability assessments[4].

Technological Advancements

Technological advancements are also playing a crucial role in the transition away from trypan blue.

Automated Cell Counting

Automated cell counting systems using machine learning models have been developed to improve the accuracy and efficiency of cell counting. These systems can perform cell counts with high accuracy and reduce the subjective variability associated with manual counting using trypan blue[5].

Key Takeaways

  • Trypan blue's toxicity and accuracy issues have led to a decline in its use.
  • Regulatory changes and safety concerns have increased operational costs and reduced demand.
  • Alternatives like fluorometric assays and propidium iodide offer improved accuracy and safety.
  • Technological advancements in automated cell counting are further reducing the reliance on trypan blue.

FAQs

What are the primary concerns with using trypan blue for cell viability?

The primary concerns include its toxicity to cells, which affects the accuracy of viability measurements, and the subjective interpretation of staining patterns under bright-field microscopy.

Why is trypan blue classified as a carcinogen?

Trypan blue is classified as a Group 2B carcinogen by the European Chemical Agency (ECHA) because it may cause cancer, genetic defects, and damage fertility or harm an unborn child.

What are some safer alternatives to trypan blue?

Safer alternatives include fluorometric assays using dyes like acridine orange (AO) and 4′,6-diamidino-2-phenylindole (DAPI), as well as propidium iodide.

How have regulatory changes impacted the use of trypan blue?

Regulatory changes have led to strict permit requirements and the need for special handling procedures, increasing operational costs and reducing demand for trypan blue.

What role do technological advancements play in the transition away from trypan blue?

Technological advancements, such as automated cell counting systems using machine learning models, have improved the accuracy and efficiency of cell counting, further reducing the reliance on trypan blue.

Sources

  1. Trypan Blue In Cell Counting And Why It Is A Bad Idea - ChemoMetec
  2. Observation and quantification of the morphological effect of trypan blue rupturing dead or dying cells - PLOS ONE
  3. Effects of trypan blue on cell viability and gene expression in human retinal pigment epithelial cells - PubMed
  4. Trypan Blue Solution for Viable Cell Counting - STEMCELL Technologies
  5. Automated cell counting for Trypan blue-stained cell cultures using machine learning - PLOS ONE

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.